The global Amyotrophic Lateral Sclerosis Treatment Market was valued at USD 594.1 Mn in 2022 and is projected to surpass USD 958.2 Mn by the end of 2031, expanding at a CAGR of 5.5% from 2023 to 2031. Market growth is driven by the rising prevalence of neurodegenerative disorders, increasing investments in advanced drug development, growing awareness about early diagnosis, and ongoing research into innovative therapies for ALS treatment worldwide.

👉 Get sample market research report copy today@ https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=65843

Market Overview

ALS primarily affects the motor neurons, which are the nerve cells responsible for transmitting signals from the brain and spinal cord to the muscles throughout the body. As the disease progresses, these motor neurons gradually degenerate and die, leading to a loss of muscle control and function.

Amyotrophic lateral sclerosis symptoms typically manifest as muscle weakness, muscle wasting, and a progressive decline in voluntary muscle control. Initial signs could include difficulty with tasks that require fine motor skills, such as buttoning a shirt or writing. As the disease progresses, individuals could experience difficulty walking, speaking, swallowing, and eventually breathing. However, cognitive function is typically preserved in most cases of ALS.

Analysts’ Viewpoint

The rise in prevalence of amyotrophic lateral sclerosis is driving the global amyotrophic lateral sclerosis (ALS) treatment market. Sporadic ALS is the most common type of ALS, which affects around 90% to 95% of total ALS patients. Increase in awareness among patients and healthcare professionals about new treatment options is expected to propel the global amyotrophic lateral sclerosis (ALS) treatment market growth. The emergence of stem cell therapy as a new treatment option for ALS is likely to bolster market expansion.

Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease, is a progressive and debilitating neurodegenerative disorder that affects the nerve cells responsible for controlling voluntary muscle movement. It was first described by French neurologist Jean-Martin Charcot in the late 19th century.

Analysis of Key Players

The landscape is shifting from generic providers to biotech innovators focusing on rare genetic markers.

Leading companies operating in the global ALS treatment market include:

• Mitsubishi Tanabe Pharma Corporation
• Otsuka Pharmaceutical Co., Ltd.
• BrainStorm Therapeutics
• Biogen, Inc.
• Corestem
• AB Science
• F. Hoffmann-La Roche AG
• Biohaven Pharmaceutical
• Sun Pharmaceutical

Strategic moves in 2026 focus on Artificial Intelligence in Drug Discovery, with companies like Verge Genomics leveraging AI to identify non-traditional biomarkers, potentially shortening discovery timelines by 30%.

Recent Developments (2025–2026)

• April 2026: NeuroSense Therapeutics released positive data from its Phase 2b PARADIGM trial, suggesting PrimeC effectively slows progression through synergistic microRNA modulation.
• March 2026: Leading academic centers in the U.S. began offering new gene therapy infusions for the 20% of cases linked to proven genetic mutations.
• January 2025: Amylyx Pharmaceuticals announced the FDA lifted the clinical hold on its AMX0114 Phase 1 trial, signaling a push for new protein-targeting mechanisms.
• Mid-2025: Canada and the EU expanded the availability of oral formulations of Edaravone, significantly boosting the parenteral-to-oral segment transition (~50.2% oral dominance).
• In April 2023, Biogen, Inc. received the USFDA approval of QALSODY for treatment of amyotrophic lateral sclerosis (ALS) in adults who have a mutation in the superoxide dismutase 1 (SOD1) gene
• In May 2022, Mitsubishi Tanabe Pharma America, Inc. received the U.S. FDA approval for RADICAVA ORS (edaravone), the oral form of edaravone, for the treatment of amyotrophic lateral sclerosis (ALS)

👉 Discuss Implications for Your Industry Request Sample Research Report PDF@ https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=65843

Key Developments & Trends

• Gene Silencing & ASOs: Growing reliance on therapies that “turn off” toxic protein production in familial cases.
• Stem Cell Regeneration: High investment in mesenchymal stromal cell research aimed at repairing damaged motor neurons.
• AI-Based Speech Analysis: Use of non-invasive digital tools to detect early bulbar-onset ALS and monitor progression.
• “Buy-and-Bill” Expansion: Streamlining hospital pharmacy reimbursement for high-cost biologic infusions.
• Multidisciplinary Clinics: Growth in specialized ALS centers that bundle medication, respiratory support, and nutrition.

Challenges

• High Attrition Rates: Approximately 90% of ALS drugs fail in clinical trials due to the disease’s complex and variable pathology.
• Diagnostic Delay: The average time from symptom onset to diagnosis remains 10–12 months, often missing the “window of opportunity” for early treatment.
• Prohibitive Pricing: New-age biologics and gene therapies can cost US$ 150k+ per year, creating significant global disparity in access.
• Lack of a Cure: Current FDA-approved therapies only slow progression (typically by 2–6 months) rather than halting or reversing the disease.

Opportunities

• Personalized Medicine: Development of therapies tailored to individual “phenotypes” (e.g., limb-onset vs. bulbar-onset).
• Retail & Online Expansion: Fastest growing CAGR in distribution as orphan drugs become more accessible via specialized home-delivery networks.
• Biomarker Discovery: Identification of blood-based neurofilament light chain (NfL) tests to monitor drug efficacy in real-time.
• Regenerative Medicine Funding: Surge in government grants and private equity for neurodegenerative disease research.

Market Segmentation

➤ By ALS Type

• Sporadic ALS (Majority Share ~68.5%)
• Familial ALS (Fastest Growing ~8.1% CAGR)

➤ By Treatment Type

• Medications (Dominant ~84.9% share)
• Stem Cell Therapy (Fastest Growth Segment)
• Others (Physical/Speech Therapy, Ventilation)

➤ By Drug Class

• Glutamate Inhibitors (Riluzole-based)
• Free Radical Scavengers (Edaravone-based – Segment Leader)
• Antisense Oligonucleotides (ASO) & Gene Therapy
• Anti-Inflammatory & Immunomodulators

➤ By Distribution Channel

• Hospital Pharmacies (Market Leader ~54.3% share)
• Retail Pharmacies (Fastest Growing CAGR)
• Online Pharmacies

Conclusion

The ALS treatment market in 2026 is moving from management to modification. Through 2035, the industry will be defined by genetic precision. As the market matures beyond generic riluzole and embraces a multi-target approach—including stem cells and gene silencing—the players that successfully integrate early biomarker diagnosis with long-term disease-modifying therapies will lead the neurodegenerative landscape.

👉 To buy this comprehensive market research report, click here to inquire@ https://www.transparencymarketresearch.com/checkout.php?rep_id=65843&ltype=S

About Transparency Market Research

Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants use proprietary data sources and various tools & techniques to gather and analyses information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Contact:

Abhishek Budholiya
Transparency Market Research Inc.
State Tower, 90 State Street, Suite 700,
Albany NY – 12207, United States
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-552-3453
Website: https://www.transparencymarketresearch.com
Sales Inquiries: sales@transparencymarketresearch.com
Media Inquiries: media@transparencymarketresearch.com